Risk-reducing salpingo-oophorectomy among diverse patients with BRCA mutations

These data are from patients with an identified hereditary breast and ovarian cancer (HBOC) gene mutation with prospectively collected qualitative interviews. This research was approved by the University of Illinois-Chicago Institutional Review Board. Subjects were identified from a database of patients seen at the University of Illinois Hospital (UIH) Familial Cancer Program from January 1, 2008 through December 31, 2019. To ensure inclusion of patients who receive care at UIH but may have been diagnosed with a gene mutation outside the Familial Cancer Program, ICD-9 and ICD-10 codes (Supplement 1) were used to identify and retrieve medical records for patients diagnosed with a hereditary genetic syndrome putting them at increased risk of ovarian cancer.Eligible patients for the retrospective cohort study had an increased risk of ovarian cancer due to pathogenic mutations in BRCA1 or BRCA2. Patients with variants of undetermined significance (VUS) BRCA1 and BRCA2 mutations were excluded given no strong evidence or recommendation for risk reducing surgery. Based on the NCCN age-specific recommendations for rrBSO in this population, BRCA1 mutation carriers under 35 years and BRCA2 mutation carriers under age 40 were excluded. Also excluded were patients with mutations categorized as variance of unknown significance (VUS), and those who already had a diagnosis of ovarian, fallopian tube, or peritoneal cancer.